NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球癌症免疫療法市場:聯合療法的增長

I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market

出版商 Frost & Sullivan 商品編碼 987570
出版日期 內容資訊 英文 164 Pages
商品交期: 最快1-2個工作天內
價格
全球癌症免疫療法市場:聯合療法的增長 I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market
出版日期: 2020年12月24日內容資訊: 英文 164 Pages
簡介

在預測期內,癌症免疫療法市場預計將以11.6%的速度增長,到2025年將增長到1326.6億美元。儘管受新型冠狀病毒感染(COVID-19)的影響在2020年有所下降,但由於研發預算的恢復和後期臨床候選藥物的發展加速,預計將從2022年開始恢復。

本報告探討了全球癌症免疫療法市場,市場定義和概述,價值鏈分析,COVID-19和其他市場影響因素,臨床試驗趨勢,監管和報銷情況以及市場,並總結了對各種因素的分析。影響增長,利潤變化/預測,按產品進行的詳細分析,競爭環境,增長機會/增長策略的分析等。

戰略要求

執行摘要

市場概述

價值鏈/研發成本

臨床試驗概述

監管/贖回場景

主要推出的藥品/管道藥品儀表板

  • 投放市場的藥物:檢查點抑製劑:sOpdivo? (nivolumab): Bristol-Myers Squibb
  • 上市藥物:檢查點抑製劑:sKeytruda? (pembrolizumab): Merck & Co
  • 投放市場的藥物:檢查點抑製劑:sYervoy? (ipilimumab): Bristol-Myers Squibb
  • 投放市場的藥物:檢查點抑製劑:sTecentriq? (atezolizumab): Roche/Genentech
  • 投放市場的藥物:檢查點抑製劑:sImfinzi? (durvalumab): AstraZeneca
  • 投放市場的藥物:過繼細胞療法:Yescarta? (KTE-C19, axicabtagene ciloleucel): Kite Pharma-Gilead
  • 投放市場的藥物:過繼細胞療法:Kymriah? (CTL019, tisagenlecleucel): Novartis
  • 上市藥物:雙特異性抗體:BLINCYTO?(Blinatumomab):Amgen
  • 管道藥物:免疫調節劑:Bempegaldesleukin(NKTR-214):Nektar Therapeutics
  • 管道藥物:免疫調節劑:Tilsotolimod (IMO-2125): Idera Pharmaceuticals
  • 管道藥物:檢查點抑製劑:Magrolimab (GS-4721): Gilead Sciences/Forty Seven
  • 管道藥物:免疫調節劑:Dostarlimab (TSR-042, WBP-285): GlaxoSmithKline
  • 管道藥物:過繼細胞療法:Lisocabtagene Maraleucel (liso-cel): Bristol-Myers Squibb
  • 管道藥物:過繼細胞療法:Idecabtagene Vicleucel (ide-cel, bb2121): Bristol-Myers Squibb
  • 管道藥物:檢查點抑製劑:Tislelizumab (BGB-A317): BeiGene
  • 管道藥物:檢查點抑製劑:Camrelizumab (AiRuiKa?, SHR-1210): Jiangsu HengRui Medicine
  • 特色公司:強大的生物技術平台
  • 特色公司:靈活的生物工程解決方案

增長機會分析:總市場

  • 調查範圍
  • 市場分類
  • 主要增長指標
  • 生長因子
  • 抑制生長
  • 預測先決條件
  • 收入預測
  • 收入預測:按產品
  • 競爭環境
  • 收入分成

生長機會分析:免疫調節劑

  • 主要增長指標
  • 收入預測
  • 預測分析
  • 批准的免疫檢查點抑製劑
  • 批准的免疫調節劑

生長機會分析:過繼細胞療法

  • 主要增長指標
  • 收入預測
  • 預測分析
  • 自體與同種異體過繼細胞療法的挑戰
  • 批准的採用細胞療法

分析增長機會:基於抗體的靶向療法

  • 主要增長指標
  • 收入預測
  • 預測分析
  • 批准的靶標單克隆抗體
  • 批准的抗體藥物偶聯物

增長機會分析:癌症疫苗和溶瘤病毒

  • 主要增長指標
  • 收入預測
  • 預測分析
  • 批准的癌症疫苗
  • 批准的溶瘤病毒

增長機會的領域

  • 增長機會1:組合療法可提高療效
  • 增長機會2:分散的衛星製造使細胞療法負擔得起
  • 增長機會3:支持精密癌症醫學的新工程平台
  • 增長機會4:生物標記物可支持伴隨診斷以預測反應並監測免疫進化
  • 增長機會5:用於標準療法的癌症免疫療法新驗證框架
  • 增長機會6:加速癌症免疫治療計劃的重點領域:亞太地區

主要公司簡介

  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Pfizer
  • Roche

下一步

目錄
Product Code: PB53-52

Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential

This study explores the global immuno-oncology (I-O) market's evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by Frost & Sullivan to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions.

The study considers oncology agents for which the immune system is the basis of their actions, including monoclonal antibodies, cell and gene therapies, bioengineered vaccines, recombinant products, small molecules, and oncolytic viruses. Classified into 5 major therapy types-immunomodulators, adoptive cell therapy, cancer vaccine, oncolytic virus, and antibody-based targeted therapies-the analysis provides revenue forecasts by global market and product category. The agents are classified into various therapy types based on the mechanism of action (MOA). Concerning pipeline products, we have considered industry-sponsored products under development.

The oncology therapeutic segment is expected to witness minimal impact from the COVID-19 pandemic because of the criticality of treating cancer patients and the segment's role as a major revenue-generator for pharmaceutical companies. Frost & Sullivan have considered the impact of COVID-19 and two scenarios for the sales forecast: original scenario and COVID-19 impact scenario.

In the original scenario, the I-O market is expected to reach $132.66 billion by 2025 growing at a rate of 11.6% and witness minimal impact from the COVID-19 pandemic, with 2020 accounting for the majority of decline. After 2022, the market will positively recuperate and experience a slight increase in revenue due to rebounding R&D budgets and accelerated developments of late-stage clinical candidates.

Research Highlights:

Major Themes Covered in This Study:

  • Strategic imperatives and key findings
  • Overview of I-O market, including the journey from bench to bedside, the value chain and stakeholder ecosystem, R&D expenditure, funding, and investment
  • Clinical trial overview for all therapies in consideration, with details for each I-O target and agent
  • Regulatory and reimbursement scenario, including risk-sharing models
  • Key marketed and pipeline products, market and technology dashboard
  • Extensive growth opportunity analysis with metrics, drivers, restraints, and competitive environment
  • Market revenue forecast and share analysis for each product segment
  • Calls to action aligned with the recommended growth opportunities
  • Key company profiles

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on the Immuno-oncology (I-O) Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Executive Summary

  • Key Findings for the Immuno-oncology Market-Rising Incidences of Cancer, R&D Portfolio Management, and Regulatory Pathways
  • Key Findings for the Immuno-oncology Market-Breakthrough Innovations, Program Acceleration, and Smart Production
  • Market Snapshot, Global Immuno-oncology Market
  • Summary of Growth Opportunities-Best Suited Therapy Design
  • Summary of Growth Opportunities-Optimal Path to Market

Market Overview-Immuno-oncology

  • Characteristics of Immuno-oncology Therapies-Journey from Bench to Bedside

Immuno-oncology Value Chain and R&D Expenditure-Immuno-oncology

  • Immuno-oncology Clinical Development Process and Approach
  • Immuno-oncology Value Chain and Stakeholder Ecosystem
  • Immuno-oncology from Early Stages to Product Launch
  • Immuno-oncology R&D Funding and Investment

Clinical Trial Overview-Immuno-oncology

  • Clinical Trials Snapshot for Immuno-oncology Therapies
  • Clinical Trials Snapshot for T-cell Targeting Immunomodulators
  • Clinical Trials Snapshot for Other Immunomodulators
  • Clinical Trials Snapshot for Adoptive Cell Therapies
  • Clinical Trials Snapshot for Targeted Cell Types
  • Clinical Trials Snapshot for Cancer Vaccines
  • Clinical Trials Snapshot for Oncolytic Viral Therapies
  • Clinical Trials Snapshot for Bispecific Antibodies (BsAbs)
  • Clinical Trials Snapshot for Immuno-oncology Agents
  • Clinical Trials Snapshot for Immuno-oncology Treatments

Regulatory and Reimbursement Scenario-Immuno-oncology

  • Regulatory Framework for Immuno-oncology Therapy Approval
  • Regulatory Approaches to Advance Immuno-oncology Therapies
  • Reimbursement Scenario across the Immuno-oncology Space
  • Risk Sharing Model for Immuno-oncology Therapies

Key Marketed and Pipeline Products Dashboard-Immuno-oncology

  • Marketed Product Dashboard-Checkpoint InhibitorsOpdivo® (nivolumab): Bristol-Myers Squibb
  • Marketed Product Dashboard-Checkpoint InhibitorsKeytruda® (pembrolizumab): Merck & Co
  • Marketed Product Dashboard-Checkpoint InhibitorsYervoy® (ipilimumab): Bristol-Myers Squibb
  • Marketed Product Dashboard-Checkpoint InhibitorsTecentriq® (atezolizumab): Roche/Genentech
  • Marketed Product Dashboard-Checkpoint InhibitorsImfinzi® (durvalumab): AstraZeneca
  • Marketed Product Dashboard-Adoptive Cell TherapyYescarta® (KTE-C19, axicabtagene ciloleucel): Kite Pharma-Gilead
  • Marketed Product Dashboard-Adoptive Cell TherapyKymriah® (CTL019, tisagenlecleucel): Novartis
  • Marketed Product Dashboard-Bispecific AntibodiesBLINCYTO® (blinatumomab): Amgen
  • Pipeline Product Dashboard-ImmunomodulatorBempegaldesleukin (NKTR-214): Nektar Therapeutics
  • Pipeline Product Dashboard-ImmunomodulatorTilsotolimod (IMO-2125): Idera Pharmaceuticals
  • Pipeline Product Dashboard-Checkpoint InhibitorMagrolimab (GS-4721): Gilead Sciences/Forty Seven
  • Pipeline Product Dashboard-ImmunomodulatorDostarlimab (TSR-042, WBP-285): GlaxoSmithKline
  • Pipeline Product Dashboard-Adoptive Cell TherapyLisocabtagene Maraleucel (liso-cel): Bristol-Myers Squibb
  • Pipeline Product Dashboard-Adoptive Cell TherapyIdecabtagene Vicleucel (ide-cel, bb2121): Bristol-Myers Squibb
  • Pipeline Product Dashboard-Checkpoint InhibitorTislelizumab (BGB-A317): BeiGene
  • Pipeline Product Dashboard-Checkpoint InhibitorCamrelizumab (AiRuiKa™, SHR-1210): Jiangsu HengRui Medicine
  • Companies to Watch in the Immuno-oncology Space-Robust Biotech Platforms
  • Companies to Watch in the Immuno-oncology Space-Flexible Bioengineering Solutions

Growth Opportunity Analysis-Global Immuno-oncology Market

  • Global Immuno-oncology Market Scope of Analysis
  • Global Immuno-oncology Market Segmentation
  • Key Growth Metrics for Immuno-oncology Market
  • Growth Drivers for Immuno-oncology Market
  • Growth Restraints for Immuno-oncology Market
  • Forecast Assumptions-Global Immuno-oncology Market
  • Forecast Assumptions-Global Immuno-oncology Market (continued)
  • Revenue Forecast-Global Immuno-oncology Market
  • Revenue Forecast by Product-Global Immuno-oncology Market
  • Revenue Forecast Analysis-Global Immuno-oncology Market
  • Competitive Environment-Global Immuno-oncology Market
  • Revenue Share-Global Immuno-oncology Market
  • Revenue Share Analysis-Global Immuno-oncology Market

Growth Opportunity Analysis-Immunomodulators

  • Key Growth Metrics for Immunomodulators
  • Revenue Forecast-Immunomodulators
  • Forecast Analysis-Immunomodulators
  • Approved Immune Checkpoint Inhibitors as I-O Therapies
  • Approved Immune Checkpoint Inhibitors as I-O Therapies (continued)
  • Approved Immune Checkpoint Inhibitors as I-O Therapies (continued)
  • Approved Immunomodulators as I-O Therapies

Growth Opportunity Analysis-Adoptive Cell Therapy

  • Key Growth Metrics for Adoptive Cell Therapy
  • Revenue Forecast-Adoptive Cell Therapy
  • Forecast Analysis-Adoptive Cell Therapy
  • Autologous vs Allogeneic Adoptive Cell Therapy Challenges
  • Approved Adoptive Cell Therapies as I-O Therapies

Growth Opportunity Analysis-Antibody-based Targeted Therapies

  • Key Growth Metrics for Antibody-based Targeted Therapies
  • Revenue Forecast-Antibody-based Targeted Therapies
  • Forecast Analysis-Antibody-based Targeted Therapies
  • Approved Targeted Monoclonal Antibodies as I-O Therapies
  • Approved Targeted Monoclonal Antibodies as I-O Therapies (continued)
  • Approved Targeted Monoclonal Antibodies as I-O Therapies (continued)
  • Approved Targeted Monoclonal Antibodies as I-O Therapies (continued)
  • Approved Antibody Drug Conjugates as I-O Therapies
  • Approved Antibody Drug Conjugates as I-O Therapies (continued)

Growth Opportunity Analysis-Cancer Vaccine and Oncolytic Virus

  • Key Growth Metrics for Cancer Vaccine and Oncolytic Virus
  • Revenue Forecast-Cancer Vaccine and Oncolytic Virus
  • Forecast Analysis-Cancer Vaccine and Oncolytic Virus
  • Approved Cancer Vaccines as I-O Therapies
  • Approved Oncolytic Virus as I-O Therapies

Growth Opportunity Universe-Immuno-oncology

  • Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020
  • Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Call to Action
  • Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combinations
  • Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combination Cases
  • Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combination Cases (continued)
  • Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020
  • Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Call to Action
  • Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Business Model
  • Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Smart Facilities
  • Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Smart Cell Cases
  • Growth Opportunity 3: Novel Engineering Platforms for Support Precision Oncology, 2020
  • Growth Opportunity 3: Novel Engineering Platforms for Supporting Precision Oncology, 2020-Call to Action
  • Growth Opportunity 3: Novel Engineering Platforms for Support Precision Oncology, 2020-Biotech Platforms
  • Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020
  • Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Call to Action
  • Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Strategies
  • Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020- Biomarkers
  • Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Relevant Cases
  • Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Relevant Cases (continued)
  • Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020
  • Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Call to Action
  • Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-New Approaches
  • Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Improved Measures
  • Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Tele-oncology Landscape
  • Growth Opportunity 6: Asia-Pacific in the Spotlight for Accelerating I-O Programs, 2020
  • Growth Opportunity 6: Asia-Pacific in the Spotlight for Accelerating I-O Programs, 2020-Call to Action

Key Company Profiles-Immuno-oncology

  • Key Global Competitors for Immuno-oncology-Amgen Dashboard
  • Key Global Competitors for Immuno-oncology-Amgen Focus
  • Key Global Competitors for Immuno-oncology-AstraZeneca Dashboard
  • Key Global Competitors for Immuno-oncology-AstraZeneca Focus
  • Key Global Competitors for Immuno-oncology-Bristol-Myers Squibb Dashboard
  • Key Global Competitors for Immuno-oncology-Bristol-Myers SquibbFocus
  • Key Global Competitors for Immuno-oncology-Daiichi Sankyo Dashboard
  • Key Global Competitors for Immuno-oncology-Daiichi Sankyo Focus
  • Key Global Competitors for Immuno-oncology-Eli Lilly Dashboard
  • Key Global Competitors for Immuno-oncology-Eli Lilly Focus
  • Key Global Competitors for Immuno-oncology-Johnson & Johnson Dashboard
  • Key Global Competitors for Immuno-oncology-Johnson & Johnson Focus
  • Key Global Competitors for Immuno-oncology-Merck & Co Dashboard
  • Key Global Competitors for Immuno-oncology-Merck & Co Focus
  • Key Global Competitors for Immuno-oncology-Novartis Dashboard
  • Key Global Competitors for Immuno-oncology-Novartis Focus
  • Key Global Competitors for Immuno-oncology-Pfizer Dashboard
  • Key Global Competitors for Immuno-oncology-Pfizer Focus
  • Key Global Competitors for Immuno-oncology-Roche Dashboard
  • Key Global Competitors for Immuno-oncology-Roche Focus

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • Legal Disclaimer